BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22030616)

  • 1. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
    Hombach AA; Abken H
    Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.
    Hombach AA; Chmielewski M; Rappl G; Abken H
    Hum Gene Ther; 2013 Mar; 24(3):259-69. PubMed ID: 23350854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
    Hombach AA; Rappl G; Abken H
    Mol Ther; 2013 Dec; 21(12):2268-77. PubMed ID: 23985696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
    Chmielewski M; Hombach AA; Abken H
    Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.
    Dumitriu IE; Baruah P; Finlayson CJ; Loftus IM; Antunes RF; Lim P; Bunce N; Kaski JC
    Circ Res; 2012 Mar; 110(6):857-69. PubMed ID: 22282196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
    Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
    Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
    Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
    J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
    Finney HM; Akbar AN; Lawson AD
    J Immunol; 2004 Jan; 172(1):104-13. PubMed ID: 14688315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells.
    Hombach AA; Heiders J; Foppe M; Chmielewski M; Abken H
    Oncoimmunology; 2012 Jul; 1(4):458-466. PubMed ID: 22754764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
    Koehler H; Kofler D; Hombach A; Abken H
    Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
    Pulè MA; Straathof KC; Dotti G; Heslop HE; Rooney CM; Brenner MK
    Mol Ther; 2005 Nov; 12(5):933-41. PubMed ID: 15979412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
    Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
    J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
    Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
    Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.